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Abstract 
Background: Neuromyelitis Optica (NMO) is a rare autoimmune disease that covers 
20-30% of diseases related to autoimmune disorders and about 1% of demyelination 
diseases. NMO symptoms are vary between individuals, there are generally 2 main 
symptoms, transverse myelitis and optic neuritis. It requires good knowledge and 
understanding of this disease so that proper management can be given as early as 
possible so as to reduce the morbidity and mortality of the disease. This article reported 
a child with NMO disease based on The Consensus of the International Panel for NMO 
Diagnosis (IPND) 2015. 
Case Presentation: An 8-year old boy with spastic tetra paresis, bilateral nervus 
opticus dysfunction, urinary retention, and allodyniaet causa suspected NMO. Patient 
received therapy using high-dose intravenous methylprednisolone and showing a 
clinical improvement. 
Conclusion: This patient was diagnosed NMO based on IPND 2015 with an unknown 
AQP4-Ab status accompanied by supporting clinical symptoms. The management of 
NMO with high-dose intravenous methylprednisolone in this patient provides a 
meaningful response to the clinical improvement of the disease. 
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INTRODUCTION 
  Neuromyelitis optica (NMO), also known as 
Devic's disease or Devic's syndrome, is an 
inflammatory autoimmune disease in the central 
nervous system (CNS) that commonly attacks the optic 
nerve and spinal cord. NMO is a rare disease, covering 
20-30% of diseases related to autoimmune disorders 
and about 1% of demyelination diseases.1-7 
 NMO is a complex disease caused by interaction 
between genetic host and environmental factor. The 
major immunological characteristic of NMO is the 
antibodyies against aquaporin 4 (AQP4-Ab), which is 
the main water channel in the brain. However, the 
absence of seropositive AQP4-Ab in some cases of 
NMO raise the suspicion that NO can be caused by 
other mechanisms, such as connective tissue disorder, 
paraneoplastic disorder, or infectious disease. This is 
strong evidence supporting the hypothesis that NMO 
has heterogeneous etiopathogenetics.8-12 
 NMO symptoms vary between individuals, 
generally there are 2 main symptoms, transverse 
myelitis (TM) and optic neuritis (ON). NMO is often 
misdiagnosed with multiple sclerosis (MS) because it 
has similar clinical presentation. Transverse myelitis on 
NMO tend to be more severe than MS. Likewise, ON in 
NMO and MS have nearly identical clinical 
presentation, but demyelination in NMO is more severe 
and destructive than MS, so determining the right 
diagnosis is very important.6-9,13,14 
 Acute phase therapy includes the administration of 
high-dose intravenous corticosteroid in the early phase, 
followed by plasma exchange and other immune 
supressive drugs to prevent the relapse. Early treatment 
is very important to minimize the damage and loss of 
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 This requires good knowledge and understanding of 
this disease so that proper management can be given as 
early as possible so as to reduce the morbidity and 
mortality due to this disease. This study will describe an 




 An 8-year-old boy came to the Emergency Room 
(ER) of Dr. Kariadi Hospital, Semarang, Indonesia with 
the main complaint of weakness of the four limbs for 13 
days before entering the hospital. He was admitted 
suddenly weak in the right leg and left arm which were 
then followed by weakness in the left leg and right arm. 
Weakness started from the tip of the arm and leg, slowly 
rises to the top. Both eyes were blurred and pain around 
the eyeballs when glancing. The patient said that the 
body felt pain in all over the body and the pain was 
increased when the body was touched. The patient 
complained that he was difficult to urinate, and had to 
push first so that he could urinate. The was no 
abnormality in defecation. Previously, he was 
hospitalized in private hospital Tegal for 7 days without 
any improvement, then he referred to Dr. Kariadi 
Hospital in Semarang.  
 Physical examination in the ED revealed blood 
pressure100/70mmHg, pulse rate was 98 times per 
minute, breathing rate was 22 times per minute, body 
temperature was 36.5oC, and body weight was 43 kg. 
Neurological examination results were: GCS was 
E4M6V5, numeric rating scale (NRS) pain scale was 3-
4, dysfunction of bilateral optic nerve with visual acuity 
of both eyes were 1/60 (with correction), normal result 
of visual field and colour vision, and spastic tetra paresis 
with motor strength were 3, allodynia, and urinary 
retention. The results of blood tests showed leukocytosis 
(16,600/µL). ECG examination showed normal sinus 
rhytm. Chest radiograph showed the normal heart and 
lung. Cervical X-rays showed good curvature, 
intervertebral discs within normal limit. Patients were 
diagnosed with spastic tetra paresis, bilateral nervus 
opticus dysfunction, urinary retention, and allodyniaet 
causa suspected NMO with differential diagnosis of 
multiple sclerosis (MS). 
 The treatment regimen consisted of RL infusion of 
12 drops per minute, intravenous methylprednisolone 
125 mg/12 hours, intravenous ranitidine 150 mg/12 
hours, oral paracetamol 500 mg/8 hours, and oral 
vitamin B1-B6-B12 1 tablet/8 hours. 
 Fundus colour examination (figure 1) showed that 
both optic discs were firmly bounded with CDR of 0.3-
0.4, no glaucomatous excavation, arterial-venous ratio 
and vessels structure within normal limit, and neither 
retinal bleeding nor retinal detachment were present. 
Head MRI with contras showed a normal result (figure 
2). No visible thickening, irregularity, changes in signal 
intensity, or pathological contrast enhancement in both 
optic nerve. There were no retro-bulbar mass, no 
intracranial space occupying lesion, no infarction, 
bleeding, or signs of increased intracranial pressure. The 
whole spine MRI with contrast (figure 3) showed no 
lesions or masses in the spinal cord, and within intra or 
extra dural of the spine. 
 During 16 days of treatment, the patient's condition 
was improved in neurological status, motor strength of 
the upper limb was 5 and lower limb was 4, and visual 
acuity of both eyes improved to 6/6. The pain in the body 
and the eyes were reduced, and urinary function was 
improved as well. After 6 days of treatment, 
methylprednisolone injection was tapering off and 
continued with oral methylprednisolone. 
 
 
Figure 1.Fundus colour examinations showed normal results 
 
 
Figure 2. Head MRI results with contrast showed normal 
results 
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DISCUSSION 
 NMO is a rare disease. NMO can affect men and 
women, in the age of 3-80 years. In preadolescent 
children, there are no gender predilection. But after the 
adolescence phase, women dominate around 70-90% of 
all individuals affected by this disease.1-11,14 In Europe, 
NMO is very rare in the pediatric population, a cohort 
study in pediatric patients in Germany shows an age 
range from 5-14 years.13 Population-based studies in 
Europe and Asia reported that incidence and prevalence 
of NMO ranges from 0.05-0.4 and 0.52-4.4 per 
100.000.15There were no differences in incidence and 
prevalence of NMO in Asia compared to others; 
although ethnicity, genetic, and environmental factor 
may influence on disease phenotype and clinical 
outcome.15-16 
 NMO symptoms vary between individuals, there are 
generally 2 main symptoms, namely transverse myelitis 
(TM) and optic neuritis (ON). TM is an acute 
inflammatory process involving a focal area in the spinal 
cord with clinical characteristics of either acute or sub-
acute development of signs and symptoms of 
neurological dysfunction of the motor, sensory and 
autonomic nerves in the spinal cord.17 In this patient, 
there was a sudden weakness of the limbs, gradually in 
the left arm and right leg followed by the left leg and 
right arm,in which the weakness were getting heavier 
gradually. Sensory involvement can be found in the form 
of allodynia where pain was felt throughout the body and 
pain increased when the body was touched. Impaired 
autonomic function is indicated by the presence of 
urinary or alvi retention. Both visual acuity in this patient 
was accompanied by ocular pain. Generally, ON was 
acute, severe visual disturbance without significant 
findings on ocular examination, and is caused by a direct 
autoimmune reaction in the optic nerve.18,19 Clinical 
manifestations of optic neuritis include symptoms and 
signs of a sharp decrease in visual acuity, mild pain 
around or behind the eyeball, impaired visual field, 
decreased contrast sensitivity, impaired color vision, 
pupillary abnormalities, and fundal findings is the form 
of lesion near the optic nerve papillary.20-22 
 MRI is the main modality examination for the 
diagnosis of NMO, which will indicate an inflammation 
signs of the brain and spinal cord, which appears as a 
white area. Spinal MRI of patient showed no sign of 
inflammation in 3 or more segments of the spinal cord 
(longitudinally extensive transverse myelitis), where as 
in brain MRI there was also no picture of lesions typical 
of NMO which are usually located in the hypothalamus, 
corpus callosum, periventricular or brain stem.2-4 LCS 
examination was not done due to the patient's condition 
impossible to do it. LCS examination of NMO usually 
showed pleocytosis (> 50 cell /mm3) with predominant 
neutrophil and an increase in protein (100-500 mg/dl). 
Although rare, oligoclonal bands can be found in NMO 
(15-30%) but this is more common in multiple sclerosis. 
Unfortunately, anti-AQP4 examination can not be 
examine in the Dr. Kariadi Hospital. In fact, AQP4-Ab 
examination of NMO cases was reported to had 
sensitivity of 76.7% and specificity of 99.8%.11-14,24 
 The International Panel for NMO Diagnosis (IPND) 
revised the consensus about clinical diagnosis of 
neuromyelitis Optica spectrum disorder (NMOSD) in 
2015 (Table 1). In accordance with the consensus, this 
patient could be included in an NMO diagnosis with an 
unknown AQP4-Ab status with supporting clinical 
symptoms. The main differential diagnosis in this patient 
Table 1. The International Panel for NMOSD Diagnosis 201514,25 
Diagnosis with AQP4-Abs 
• at least one core clinical characteristic 
• positive AQP4-Abs with best available method 
• exclusion of alternative diagnosis (e.g. sarcoidosis, neoplastic/paraneoplastic, vascular, chronic infection) 
Diagnosis without AQP4-Abs/unknown status 
• at least two core clinical characteristics resulting from one or more clinical attacks and fulfilling the 
following: 
a. at least one of optic neuritis, LETM, APS 
b. dissemination in space (2/more different core clinical characteristics) 
c. fulfillment of additional MRI requirements as applicable 
• negative for AQP4-Abs with best available method, or testing unavailable 
• exclusion of alternative diagnoses 
Core clinical characteristics 
• optic neuritis 
• acute myelitis 
• APS 
• brainstem syndrome 
• symptomatic narcolepsy or acute diencephalic syndrome with NMOSD-typical diencephalic MRI lesions 
• symptomatic cerebral syndrome with NMOSD-typical brain lesions 
Additional MRI requirements for NMOSD without AQP4-Abs/unknown status 
• acute optic neuritis: normal or only nonspecific white matter lesions on MRI brain; or optic nerve MRI 
with T2-hyperintense lesion or T1-weighted gadolinium-enhancing lesion extending over>1/2 optic nerve 
length or optic chiasm involvement. 
• acute myelitis: MRI spinal cord demonstrating attack-associated lesion spanning ≥ 3 contiguous vertebral 
segments (LETM); or ≥ 3 contiguous segments of focal cord atrophy with previous history of acute 
myelitis 
• APS: dorsal medulla/area postrema lesion on MRI brain 
• acute brainstem syndrome: peri ependymal brainstem lesions. 
APS: area postrema syndrome, AQP4-Abs: aquaporin-4 antibodies, LETM: longitudinally extensive transverse 
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is MS. NMO and MS have very similar clinical features, 
but in this patient the course of the disease was 
monophasic and the findings on head and whole spine 
MRI with contrast are not typical for MS, therefore the 
diagnosis of this patient was NMO.14,25 
 Patients received high-dose intravenous 
methylprednisolone therapy (125mg/12 hours) and 
tapering off for 6 days then continued with oral 
administration of methylprednisolone. Evaluation 
showed that there was clinical improvement. Visual 
acuity gradually improved, where at the beginning of 
treatment visual acuity of the right and left eye were 1/60 
improved to 3/60, and at the end of visual acuity were 
6/6. Motor strength also showed improvement in all four 
limbs. Evaluation of sensoric function showed an 
improvement in which patient who initially experienced 
pain throughout the body, at the end of the treatment 
there was a decrease in pain scale and no pain when light 
touch. Evaluation of autonomic function showed that the 
urinary function had improved.11-14 
 Based on multicenter study of MS and NMO had 
been reported that intravenous methylprednisolone 
therapy was effective as first-line therapy in NMO but 
was more effective in MS patients compared to NMO.3,4 
When the patient's condition did not improve or even 
worsened after corticosteroid therapy, it is recommended 
to do therapeutic plasma exchange (TPE) for 5-7 cycles. 
TPE has also been used concurrently or immediately 
after glucocorticoid therapy in progressive or refractory 
conditions. The results of a study showed that TPE as 
early as possible (≤ 5 days) is more beneficial than TPE 
delays in cases of NMO refractory to intravenous 
methylprednisolone.2-4,11-14 IVIG is another important 
therapy that can affect various immunomodulatory 
pathways and antigenic-recognition, including humoral 
and cellular immunity. Several immunosuppressive 
agents (steroid, azathioprine, rituximab, and 
mycophenolate mofetil) have also been accepted as 
long-term therapy for NMO patients.11-14 
 
CONCLUSION 
 This patient was diagnosed neuromyelitis optica 
(NMO) based on diagnostic criteria of the International 
Panel for NMO Diagnosis (IPND) 2015 with an 
unknown AQP4-Ab status, supporting by clinical 
symptoms. The management of NMO with high-dose 
intravenous methylprednisolone has meaningful 
response to the clinical improvement. After intravenous 
methylprednisolone for 6 days, steroid was tapering off 
and continued by oral methypredinisolone. 
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